Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer

Ferrari, P; Castagnetti, G.; Pollastri, C. A.; Ferrari, G.; Tavoni, F.; Grassi, Davide

doi:10.1097/00001813-199205000-00006

Cited by 22 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serreta and Ferrari et al have investigated the potential benefits of epirubicin and interferon‐2‐alpha and have reported better results in combination group, albeit the differences were not statistically significant and the follow‐up period was not long enough to be conclusive. 11,12 They have also found that the immune response to interferon‐2‐alpha was augmented when combined with epirubicin. Rentala et al have reported their experience on combination of BCG and mitomycin‐C.…”

Section: Discussionmentioning

confidence: 97%

Clinical experience with BCG alone versus BCG plus epirubicin

Bilen¹,

Ozen²,

Aki.³

et al. 2000

Int J of Urology

View full text Add to dashboard Cite

Background: Bacillus Calmette-Guérin (BCG) and epirubicin have both been shown to be effective in the treatment of superficial bladder cancer. We studied whether the alternating combination of these agents could improve the efficacy with tolerable side-effects in the treatment of high-risk superficial bladder tumors. Methods: Forty-one patients with high-risk superficial bladder transitional carcinoma were included in this study. Twenty-one patients were randomized into the BCG group and 20 patients were treated with sequential BCG and epirubicin. The patients were followed for 9-24 months (mean 18 months). Recurrence rates, median time to the first recurrence, progression rate and complications were compared.Results: Fifteen percent of the patients in the BCG and epirubicin group and 19% of the patients in the BCG alone group developed tumor recurrence. Tumor progression was observed in 4.7% and 10% in the BCG/epirubicin group and the BCG alone group, respectively. Median time to first recurrence was 11 months for the BCG/epirubicin group and 16 months for the BCG group (P > 0.05). Three patients in the BCG/epirubicin treatment group developed serious side-effects, which necessitated antituberculosis treatment. Conclusion:Because the efficacy of combination was no better than the standard treatment and the alternating combination seemed to be related to a higher incidence of side-effects, this study albeit small, does not recommend combination therapy of BCG and epirubicin in high risk patients with superficial bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

Clinical experience with BCG alone versus BCG plus epirubicin

Bilen¹,

Ozen²,

Aki.³

et al. 2000

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…The optimal dose and schedule of interferon remains to be defined. Combination treatment of interfer on with cytostatics intravesically is scarcely investigated and the results are not yet conclusive [43][44][45], TUR alone when adjuvant intravesical instillation of cytotoxic agents or immunomodulators is added. Patient characteristics are important factors in determining which patients and how far they might benefit from adju vant treatment (table 2).…”

Section: Intravesical Treatmentmentioning

confidence: 99%

Diagnosis and Treatment of Superficial Transitional Cell Carcinoma of the Bladder: Facts and Perspectives

Kh¹

1997

Eur Urol

View full text Add to dashboard Cite

“…Intravesical immunotherapy with alpha2b-interferon (alpha2b-IFN) has been shown to be of comparable efficacy to conventional chemotherapy, with a low incidence of systemic or local adverse effects [7]. Interferon has also been used succesfully in combination with chemotherapeutic drugs such as mitomycin C and epirubicin [8,12]. Although the Accepted for publication 22 August 1995 © 1995 British Journal of Urology rate were calculated to assess the behaviour of the disease.…”

Section: Introductionmentioning

confidence: 99%